08:01 AM EST, 11/05/2025 (MT Newswires) -- Biohaven ( BHVN ) shares were 43% lower pre-bell Wednesday after the company said late Tuesday the US Food and Drug Administration has recommended a meeting to discuss the evidence that will be required to support a future new drug application for spinocerebellar ataxia.

Trex (TREX) stock was down 35%, a day after the company reported Q3 financial results that trailed analysts' estimates.

Soleno Therapeutics ( SLNO ) shares were 22% lower after a 2.7% loss in the previous session.